- Fresenius SE & Co. KGaA
- Akorn Inc.
- Merck KGaA
- AstraZeneca PLC
- Ionis Pharmaceuticals Inc.
- Biogen Inc.
- Bavarian Nordic AS
- Georgetown University
- Merck & Co. Inc.
- Tesaro Inc.
- Genentech Inc.
- Clovis Oncology Inc.
- Aldeyra Therapeutics Inc.
- Johnson & Johnson Innovation - JJDC Inc.
- Allergan PLC
- Shire PLC
- Janssen R&D LLC
- Bristol-Myers Squibb Co.
- Domain Therapeutics SA
- Biohaven Pharmaceutical Holding Co. Ltd.
- Catalent Inc.
- Yale University
- Amunix Pharmaceuticals Inc.
- Eli Lilly & Co.
- Johnson & Johnson
- WhanIn Pharmaceutical Co. Ltd.
- Bial-Portela & CA SA
- Mundipharma Pty. Ltd.
- Tolmar Australia Pty. Ltd.
- Tolmar Holding Inc.
- Sam Chun Dang Pharm. Co. Ltd.
- Glenmark Pharmaceuticals Ltd.
- Tetraphase Pharmaceuticals Inc.
- Everest Medicines Ltd.
- Arena Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Kite Pharma Inc.
- Sangamo Therapeutics Inc.
- Kolmar Korea Co.
- Wave Life Sciences Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Voyager Therapeutics Inc.
- AbbVie Inc.
- AstraZeneca licenses ISIS-STAT3 and other antisense projects from Isis; deal expanded to include new therapy areas
- Biohaven in-licenses CNS compounds BHV3000, BHV3500 from BMS; later restructures deal
- Biohaven licenses Catalent's Zydis technology for BHV0223
- Yale University grants Biohaven exclusive IP rights
- Amunix helps Lilly develop XTEN-based diabetes therapy
- Janssen Biotech teams up with Amunix to create protein therapeutics
- Amunix, Biogen collaborate on recombinant blood factors for hemophilia
- Everest gets rights to Arena's ralinepag and etrasimod in Greater China
Ask The Analyst
Please Note: Click here for more information on the Ask the Analyst service.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.